• Daehan New Pharm controlling shareholder Lee Wan Jin kept his stake unchanged at 5,883,557 shares, or 40.99%, as of Oct. 1.
• Shares pledged under major contracts rose to 1,614,537 shares from 1,514,537 shares, lifting the pledged ratio to 11.25% from 10.55%.
• The filing cited an extension of share pledge agreements as the reason for the change, with the obligation date set at Sept. 28.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Daehan New Pharm Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261001000420), on October 01, 2026, and is solely responsible for the information contained therein.